Marksans Pharma Ltd. - Research Center

---

Results

• Quarterly
• Half yearly
• Annual

Statement

• Balance sheet
• P&L
• Cash flow

More

• Dividend
• Share holding
• Capital structures
• Ratio

Mar' 24	Dec' 23	Sep' 23	Jun' 23	Mar' 23

Sales

225.20

241.36

204.67

182.04

153.05

Operating profit

33.91

41.98

37.30

26.76

22.71

Interest

0.23

0.27

0.23

0.26

0.66

Gross profit

45.87

43.03

53.00

59.12

26.35

EPS (Rs)

0.73

0.56

0.69

0.98

0.39

Other income

12.19

1.33

15.93

32.62

4.30

Stock adjustment

-2.13

-1.46

-5.90

2.25

-7.38

Raw material

104.36

117.16

102.83

82.80

85.36

Power and fuel

-

-

-

-

-

Employee expenses

21.56

20.47

18.23

16.93

15.42

Excise

-

-

-

-

-

Admin and selling expenses

-

-

-

-

-

Research and development expenses

-

-

-

-

-

Expenses capitalised

-

-

-

-

-

Other expenses

67.50

63.22

52.21

53.32

36.94

Provisions made

-

-

-

-

-

Depreciation

7.47

8.43

8.50

4.72

3.51

Taxation

5.41

9.31

13.21

10.20

5.04

Net profit / loss

32.99

25.29

31.29

44.19

17.81

Extra ordinary item

-

-

-

-

-

Prior year adjustments

-

-

-

-

-

Equity capital

45.32

45.32

45.32

45.32

45.32

Equity dividend rate

-

-

-

-

-

Agg.of non-prom. shares (Lacs)

-

-

-

-

-

Agg.of non promotoholding (%)

-

-

-

-

-

OPM (%)

15.06

17.39

18.22

14.70

14.84

GPM (%)

19.32

17.73

24.02

27.54

16.75

NPM (%)

13.90

10.42

14.18

20.59

11.32